Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager

Nykode Therapeutics ASA

OSE:NYKD

Watchlist

Dividends

Price: 2.812 NOK 4.38% Market Closed

Market Cap: 918.2m NOK

Have any thoughts about
Nykode Therapeutics ASA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication

Add Price Alert

Price Target:

Last Price: 2.812 NOK

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

NYKD Alert

Nykode Therapeutics ASA

2.812

+0.118 (+4.38%)

52 Week Range	2.134 21.4
Price Target

We'll email you a reminder when the closing price reaches NOK.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Berkshire Hathaway Inc NYSE:BRK.A	US
	Bank of America Corp NYSE:BAC	US
	Mastercard Inc NYSE:MA	US
	UnitedHealth Group Inc NYSE:UNH	US
	Exxon Mobil Corp NYSE:XOM	US
	Pfizer Inc NYSE:PFE	US
	Palantir Technologies Inc NYSE:PLTR	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Walmart Inc NYSE:WMT	US
	Verizon Communications Inc NYSE:VZ	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Nykode Therapeutics ASA

What unique competitive advantages
does Nykode Therapeutics ASA hold over its rivals?

What risks and challenges
does Nykode Therapeutics ASA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Nykode Therapeutics ASA.

What unique competitive advantages
does Nykode Therapeutics ASA hold over its rivals?

What risks and challenges
does Nykode Therapeutics ASA face in the near future?

Summarize the latest earnings call
of Nykode Therapeutics ASA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nykode Therapeutics ASA.

Provide P/S
for Nykode Therapeutics ASA.

Provide P/E
for Nykode Therapeutics ASA.

Provide P/OCF
for Nykode Therapeutics ASA.

Provide P/FCFE
for Nykode Therapeutics ASA.

Provide P/B
for Nykode Therapeutics ASA.

Provide EV/S
for Nykode Therapeutics ASA.

Provide EV/GP
for Nykode Therapeutics ASA.

Provide EV/EBITDA
for Nykode Therapeutics ASA.

Provide EV/EBIT
for Nykode Therapeutics ASA.

Provide EV/OCF
for Nykode Therapeutics ASA.

Provide EV/FCFF
for Nykode Therapeutics ASA.

Provide EV/IC
for Nykode Therapeutics ASA.

Show me price targets
for Nykode Therapeutics ASA made by professional analysts.

What are the Revenue projections
for Nykode Therapeutics ASA?

How accurate were the past Revenue estimates
for Nykode Therapeutics ASA?

What are the Net Income projections
for Nykode Therapeutics ASA?

How accurate were the past Net Income estimates
for Nykode Therapeutics ASA?

What are the EPS projections
for Nykode Therapeutics ASA?

How accurate were the past EPS estimates
for Nykode Therapeutics ASA?

What are the EBIT projections
for Nykode Therapeutics ASA?

How accurate were the past EBIT estimates
for Nykode Therapeutics ASA?

Compare the revenue forecasts
for Nykode Therapeutics ASA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nykode Therapeutics ASA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nykode Therapeutics ASA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nykode Therapeutics ASA compared to its peers.

Compare the P/E ratios
of Nykode Therapeutics ASA against its peers.

Discuss the investment returns and shareholder value creation
comparing Nykode Therapeutics ASA with its peers.

Analyze the financial leverage
of Nykode Therapeutics ASA compared to its main competitors.

Show all profitability ratios
for Nykode Therapeutics ASA.

Provide ROE
for Nykode Therapeutics ASA.

Provide ROA
for Nykode Therapeutics ASA.

Provide ROIC
for Nykode Therapeutics ASA.

Provide ROCE
for Nykode Therapeutics ASA.

Provide Gross Margin
for Nykode Therapeutics ASA.

Provide Operating Margin
for Nykode Therapeutics ASA.

Provide Net Margin
for Nykode Therapeutics ASA.

Provide FCF Margin
for Nykode Therapeutics ASA.

Show all solvency ratios
for Nykode Therapeutics ASA.

Provide D/E Ratio
for Nykode Therapeutics ASA.

Provide D/A Ratio
for Nykode Therapeutics ASA.

Provide Interest Coverage Ratio
for Nykode Therapeutics ASA.

Provide Altman Z-Score Ratio
for Nykode Therapeutics ASA.

Provide Quick Ratio
for Nykode Therapeutics ASA.

Provide Current Ratio
for Nykode Therapeutics ASA.

Provide Cash Ratio
for Nykode Therapeutics ASA.

What is the historical Revenue growth
over the last 5 years for Nykode Therapeutics ASA?

What is the historical Net Income growth
over the last 5 years for Nykode Therapeutics ASA?

What is the current Free Cash Flow
of Nykode Therapeutics ASA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nykode Therapeutics ASA.

P/FCFE
Price to FCFE

-0.9

Current

-5.1

Median

25.2

Industry

Higher than median

Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE

-0.9

Market Cap

918.2m NOK

FCFE

-89.6m USD

All Countries

Forward Multiples

			Market Cap	P/FCFE
NO	N	Nykode Therapeutics ASA OSE:NYKD	918.2m NOK	-0.9
FR		Pharnext SCA OTC:PNEXF	6T USD	-3 203 184.8
US		Abbvie Inc NYSE:ABBV	325.5B USD	13
US		Amgen Inc NASDAQ:AMGN	150.4B USD	25.4
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	120.9B USD	-90.6
US		Gilead Sciences Inc NASDAQ:GILD	115.7B USD	11.5
US	E	Epizyme Inc F:EPE	94.1B EUR	-428.4
AU		CSL Ltd ASX:CSL	135.7B AUD	79.7
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	83.7B USD	25.1
US	S	Seagen Inc F:SGT	39.3B EUR	-58.9
NL		argenx SE XBRU:ARGX	34.6B EUR	-109.7


NO	N	Nykode Therapeutics ASA OSE:NYKD	Average P/FCFE: 30.9 Negative Multiple: -0.9
FR		Pharnext SCA OTC:PNEXF	Negative Multiple: -3 203 184.8
US		Abbvie Inc NYSE:ABBV	13
US		Amgen Inc NASDAQ:AMGN	25.4
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	Negative Multiple: -90.6
US		Gilead Sciences Inc NASDAQ:GILD	11.5
US	E	Epizyme Inc F:EPE	Negative Multiple: -428.4
AU		CSL Ltd ASX:CSL	79.7
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	25.1
US	S	Seagen Inc F:SGT	Negative Multiple: -58.9
NL		argenx SE XBRU:ARGX	Negative Multiple: -109.7

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

P/FCFE

N/A

2-Years Forward

P/FCFE

N/A

3-Years Forward

P/FCFE

N/A

Nykode Therapeutics ASA
OSE:NYKD

P/FCFE
Price to FCFE

P/FCFE Forward Multiples

See Also

Company

Help

Tools

Stocks

Nykode Therapeutics ASA OSE:NYKD

P/FCFE Price to FCFE

P/FCFE Forward Multiples

See Also

Company

Help

Tools

Stocks

Nykode Therapeutics ASA
OSE:NYKD

P/FCFE
Price to FCFE